Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Peerlinck

Showing results (11-20 of 82) with videos related to

Pageof 9
Sort By:
Lancet (London, England)|February 1, 1992
Factor VIII solutions in pre-filled syringesK Peerlinck, J Arnout, J Vermylen
Bailliere'S Clinical Haematology|March 31, 1999
Inhibitory and activating human antiplatelet antibodiesH Deckmyn, K Vanhoorelbeke, K Peerlinck
Blood|June 15, 1993
Incidence of inhibitor development in a group of young hemophilia A patients treated exclusively with lyophilized cryoprecipitateK Peerlinck, F R Rosendaal, J Vermylen
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 5, 2013
Practical and cost-effective measurement of B-domain deleted and full-length recombinant FVIII in the routine haemostasis laboratoryM Cauchie, J Toelen, K Peerlinck, et al.
International Journal of Laboratory Hematology|May 10, 2018
New challenges and best practices for the laboratory monitoring of factor VIII and factor IX replacementD Van den Bossche, K Peerlinck, M Jacquemin
Lancet (London, England)|October 30, 1993
Factor VIII inhibitorK Peerlinck, J Vermylen, F Rosendaal, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 14, 2016
Medical co-morbidities of patients with haemophilia: pain, obesity and hepatitis CM L Witkop, K Peerlinck, B A Luxon
Vox Sanguinis|January 1, 1994
Is the apparent outbreak of hepatitis A in Belgian hemophiliacs due to a loss of previous passive immunity?K Peerlinck, P Goubau, G Coppens, et al.
Thrombosis and Haemostasis|March 1, 1995
Parvovirus B19 antibodies in patients with haemophilia AK Peerlinck, P Goubau, R Reybrouck, et al.
The Journal of Clinical Investigation|January 1, 1993
A monoclonal antibody recognizes a von Willebrand factor domain within the amino-terminal portion of the subunit that modulates the function of the glycoprotein IB- and IIB/IIIA-binding domainsI Tornai, J Arnout, H Deckmyn, et al.
Pageof 9

Showing results (11-20 of 82) with videos related to

Sort By:
Pageof 9
Lancet (London, England)|February 1, 1992
Factor VIII solutions in pre-filled syringesK Peerlinck, J Arnout, J Vermylen
Bailliere'S Clinical Haematology|March 31, 1999
Inhibitory and activating human antiplatelet antibodiesH Deckmyn, K Vanhoorelbeke, K Peerlinck
Blood|June 15, 1993
Incidence of inhibitor development in a group of young hemophilia A patients treated exclusively with lyophilized cryoprecipitateK Peerlinck, F R Rosendaal, J Vermylen
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 5, 2013
Practical and cost-effective measurement of B-domain deleted and full-length recombinant FVIII in the routine haemostasis laboratoryM Cauchie, J Toelen, K Peerlinck, et al.
International Journal of Laboratory Hematology|May 10, 2018
New challenges and best practices for the laboratory monitoring of factor VIII and factor IX replacementD Van den Bossche, K Peerlinck, M Jacquemin
Lancet (London, England)|October 30, 1993
Factor VIII inhibitorK Peerlinck, J Vermylen, F Rosendaal, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 14, 2016
Medical co-morbidities of patients with haemophilia: pain, obesity and hepatitis CM L Witkop, K Peerlinck, B A Luxon
Vox Sanguinis|January 1, 1994
Is the apparent outbreak of hepatitis A in Belgian hemophiliacs due to a loss of previous passive immunity?K Peerlinck, P Goubau, G Coppens, et al.
Thrombosis and Haemostasis|March 1, 1995
Parvovirus B19 antibodies in patients with haemophilia AK Peerlinck, P Goubau, R Reybrouck, et al.
The Journal of Clinical Investigation|January 1, 1993
A monoclonal antibody recognizes a von Willebrand factor domain within the amino-terminal portion of the subunit that modulates the function of the glycoprotein IB- and IIB/IIIA-binding domainsI Tornai, J Arnout, H Deckmyn, et al.
Pageof 9